Valuation: ICAD

Market Cap 106M 92.07M 86.71M 78.97M 148M 10.12B 148M 1.04B 400M 5.15B 397M 388M 16.63B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.38M 72.88M 66.37M 124M 8.5B 125M 873M 336M 4.33B 333M 326M 13.98B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
12.6
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 09/03/2023
Director of Finance/CFO 54 16/07/2025
Corporate Secretary - 16/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
17/07/25 Issuer sale

Director

1,553,657 5.8540%
17/07/25 Issuer sale

Chief Financial Officer

158,488 0.5972%
17/07/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+109.19% 106M
+1.12%+7.36%+37.36%+31.33% 244B
+1.90%+6.19%+11.67%-13.54% 152B
+2.12%+6.27%-8.45%+41.25% 142B
+0.88%-2.95%-55.31%-18.99% 63.36B
+0.09%+3.30%+18.72%+25.88% 50.92B
-0.28%-2.91%-19.55%-20.50% 48.47B
+3.50%+10.31%+28.20%+47.58% 45.66B
+0.54%+3.39%+40.90%+57.67% 41.65B
-0.33%+14.70%+132.43%+79.12% 36.06B
Average +0.80%+4.35%+18.60%+33.90% 82.34B
Weighted average by Cap. +0.13%+5.46%+16.93%+21.85%

Financials

2023 2024
Net sales 17.32M 15.1M 14.22M 12.95M 24.28M 1.66B 24.31M 170M 65.64M 845M 65.05M 63.61M 2.73B 19.61M 17.1M 16.1M 14.66M 27.49M 1.88B 27.53M 193M 74.32M 957M 73.65M 72.02M 3.09B
Net income -4.85M -4.23M -3.98M -3.62M -6.8M -464M -6.8M -47.67M -18.37M -237M -18.21M -17.8M -763M -5.62M -4.9M -4.61M -4.2M -7.87M -538M -7.88M -55.23M -21.29M -274M -21.1M -20.63M -884M
Net Debt -21.21M -18.49M -17.42M -15.86M -29.74M -2.03B -29.78M -209M -80.39M -1.04B -79.67M -77.9M -3.34B -16.84M -14.69M -13.83M -12.6M -23.62M -1.61B -23.65M -166M -63.85M -822M -63.27M -61.87M -2.65B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!